Biotech Values

[WorstLuck]

That is a summary, yes.

https://finance.yahoo.com/news/revance-provides-corporate-investor-day-130000829.html

Q3 2023 product revenue has the potential to be around Q2 2023 levels based on the recent roll out of the new pricing program and traditional seasonality in facial injectables.

Don't want to get caught up in the weeds when there is a kitchen sink type of dump like today, but the word 'potential' sounds like Q3 has a fair chance to come up short of Q2. Just confirms how disappointing the launch was.

Have expectations been sufficiently reset?

What will Q3 numbers look like? Will it matter? Did they under promise?